Anti-phospholipid antibodies are associated with response to interferon-betaia treatment in MS: Results from a 3-year longitudinal study

Robert Zivadinov, Murali Ramanathan, Julian Ambrus, Sara Hussein, Deepa P. Ramasamy, Michael G. Dwyer, Niels Bergsland, Alireza Minagar, Bianca Weinstock-Guttman

Research output: Contribution to journalArticlepeer-review


Objectives: To prospectively investigate the associations of baseline serum anti-phospholipid antibody (APLA) status on evolution of clinical and MRI measures in a multiple sclerosis (MS) patient cohort treated with interferon-beta (IFN-beta). Methods: Forty-seven relapsing-remitting (RR) MS patients, [26 APLA-positive (APLA+) and 21 APLA- negative (APLA2)] matched for age, sex, disease duration, MRI characteristics, disability, and time on IFN- beta treatment, were enrolled. All patients were on intramuscular (IM) IFN-betala for at least 3 years and remained on the same treatment over the 3-year duration of the study. Results: The APLA+ group accumulated significantly higher T2-LV over the 3-year follow-up than the APLA2 group (+ 31% versus -1.1%, P=0.043). The MTR of T1-LV (-3.3% versus +4.7%, P=0.04) in the APLA+ group was lower compared to the APLA- group. At 3-year follow-up, the APLA+ group had increased tissue damage as measured by diffusion entropy (+ 4% versus -2.5%, P=0.019) and whole brain volume loss (-0.69% versus -0.37%, P=0.041), compared to the APLA- group. There were more clinical relapses in the MS APLA+ group compared to APLA- patients (18 versus 10) and a higher frequency of sustained disability progression (7/26 or 27% versus 2/21 or 9.5%). Conclusions: This study suggests that APLA+ RRMS patients treated with IFN-beta1a develop more severe MRI and clinical deterioration. Future studies are required to evaluate the role of APLA as potential biomarkers for disease prognosis versus predictors for therapeutic response to IFN-beta therapy.

Original languageEnglish
Pages (from-to)761-769
Number of pages9
JournalNeurological Research
Issue number8
Publication statusPublished - Oct 2012


  • Anti-phospholipid antibodies
  • Atrophy
  • Diffusion-weighted imaging
  • Disability
  • IFN-beta1a
  • Lesions
  • Longitudinal
  • Magnetization transfer imaging
  • Multiple sclerosis
  • Positivity
  • Prospective
  • References
  • Relapses
  • Responsiveness

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'Anti-phospholipid antibodies are associated with response to interferon-betaia treatment in MS: Results from a 3-year longitudinal study'. Together they form a unique fingerprint.

Cite this